Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study.
作者信息
Martin R M, Kapoor K V, Wilton L V, Mann R D
机构信息
Drug Safety Research Unit, Southampton SO31 1AA.
出版信息
BMJ. 1998 Jul 11;317(7151):119-20. doi: 10.1136/bmj.317.7151.119.
Abstract
摘要
相似文献
1
Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study.
BMJ. 1998 Jul 11;317(7151):119-20. doi: 10.1136/bmj.317.7151.119.
2
Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.
Br J Clin Pharmacol. 1998 Nov;46(5):505-11. doi: 10.1046/j.1365-2125.1998.00817.x.
3
The incidence and reporting of adverse drug reactions in the Division of Psychiatry.
Pharm World Sci. 2001 Oct;23(5):181-2. doi: 10.1023/a:1012283406315.
4
Reporting suspected adverse reactions.
Vet Rec. 2019 May 18;184(20):623. doi: 10.1136/vr.l3042.
5
Adverse reactions: know the risks.
Nurs Times. 2011;107(13):20.
6
Prescription-event monitoring and reporting of adverse drug reactions.
Lancet. 2001 Dec 1;358(9296):1872-3. doi: 10.1016/S0140-6736(01)06898-2.
7
GPs are urged to report adverse drug reactions after a 37% slump over nine years.
BMJ. 2013 Feb 1;346:f690. doi: 10.1136/bmj.f690.
8
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Arch Intern Med. 2005 Jun 27;165(12):1363-9. doi: 10.1001/archinte.165.12.1363.
9
Adverse drug events: counting is not enough, action is needed.
Med J Aust. 2006 Apr 3;184(7):315-6. doi: 10.5694/j.1326-5377.2006.tb00260.x.
10
Prospective cohort study of adverse events monitored by hospital pharmacists. Hospital Adverse Event Monitoring Study (HAEMS) Group.
Pharmacoepidemiol Drug Saf. 2001 Mar-Apr;10(2):95-103. doi: 10.1002/pds.574.
引用本文的文献
1
Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database.
PLoS Negl Trop Dis. 2024 Nov 6;18(11):e0012634. doi: 10.1371/journal.pntd.0012634. eCollection 2024 Nov.
2
Sexual Dysfunction Induced by Antidepressants-A Pharmacovigilance Study Using Data from VigiBase.
Pharmaceuticals (Basel). 2024 Jun 24;17(7):826. doi: 10.3390/ph17070826.
3
Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection.
Front Psychiatry. 2021 Oct 21;12:727687. doi: 10.3389/fpsyt.2021.727687. eCollection 2021.
4
Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World.
PLoS Negl Trop Dis. 2021 Apr 20;15(4):e0009354. doi: 10.1371/journal.pntd.0009354. eCollection 2021 Apr.
5
Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial.
J Ophthalmol. 2020 Oct 6;2020:8652370. doi: 10.1155/2020/8652370. eCollection 2020.
6
Prevalence of and risk factors for adverse events in Alzheimer's patients receiving anti-dementia drugs in at-home care.
PLoS One. 2020 Apr 6;15(4):e0231226. doi: 10.1371/journal.pone.0231226. eCollection 2020.
7
Active pharmacovigilance in China: recent development and future perspectives.
Eur J Clin Pharmacol. 2018 Jul;74(7):863-871. doi: 10.1007/s00228-018-2455-z. Epub 2018 Apr 10.
8
Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation.
Pharmacoepidemiol Drug Saf. 2017 Nov;26(11):1307-1313. doi: 10.1002/pds.4304. Epub 2017 Aug 31.
9
Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
Int J Mol Sci. 2017 Jan 5;18(1):101. doi: 10.3390/ijms18010101.
10
Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England.
J Clin Hypertens (Greenwich). 2016 Dec;18(12):1237-1243. doi: 10.1111/jch.12852. Epub 2016 Jun 3.
本文引用的文献
1
United Kingdom Product Licence applications involving new active substances, 1987-1989: their fate after appeals.
Br J Clin Pharmacol. 1993 Jun;35(6):599-602. doi: 10.1111/j.1365-2125.1993.tb04188.x.
2
Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom.
Br J Clin Pharmacol. 1995 Mar;39(3):223-6. doi: 10.1111/j.1365-2125.1995.tb04440.x.
3
Review of yellow cards--1986 and 1987.
Br Med J (Clin Res Ed). 1988 May 7;296(6632):1319. doi: 10.1136/bmj.296.6632.1319.
Zotero 插件